Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$25.99 -0.9%	$23.35	$13.40 ▼ $26.65	$4.43B	0.7	2.05 million shs	1.32 million shs
AVXL Anavex Life Sciences	$9.64 +4.6%	$10.53	$4.93 ▼ $14.44	$791.94M	0.8	882,501 shs	881,720 shs
VCEL Vericel	$36.36 +1.3%	$38.39	$33.09 ▼ $63.00	$1.81B	1.27	562,643 shs	331,117 shs
XENE Xenon Pharmaceuticals	$38.71 +0.3%	$33.83	$26.74 ▼ $46.00	$2.98B	1.16	981,668 shs	677,575 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	-1.28%	+5.85%	+15.91%	+21.44%	+67.07%
AVXL Anavex Life Sciences	-2.43%	-3.46%	-18.84%	+22.44%	+56.80%
VCEL Vericel	0.00%	+1.27%	-9.96%	-14.24%	-31.73%
XENE Xenon Pharmaceuticals	-0.69%	+1.10%	+25.04%	+34.40%	-3.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	3.8626 of 5 stars	3.3	2.0	0.0	2.7	4.2	2.5
AVXL Anavex Life Sciences	3.7121 of 5 stars	3.5	1.0	4.7	2.2	0.8	0.6
VCEL Vericel	2.3129 of 5 stars	3.5	0.0	0.0	3.5	0.0	1.9
XENE Xenon Pharmaceuticals	2.2762 of 5 stars	3.5	1.0	0.0	3.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.61	Moderate Buy	$28.88	11.10% Upside
AVXL Anavex Life Sciences	3.00	Buy	$44.00	356.43% Upside
VCEL Vericel	3.00	Buy	$60.40	66.12% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$53.20	37.43% Upside

Current Analyst Ratings Breakdown

Latest AVXL, XENE, ACAD, and VCEL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00
8/22/2025	AVXL Anavex Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00
8/13/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00
8/12/2025	XENE Xenon Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00
8/12/2025	XENE Xenon Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$57.00 ➝ $55.00
8/12/2025	XENE Xenon Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$42.00 ➝ $43.00
8/8/2025	ACAD ACADIA Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$32.00 ➝ $36.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/7/2025	ACAD ACADIA Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$15.00 ➝ $17.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$39.00 ➝ $40.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $24.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	4.58	$0.70 per share	37.21	$4.87 per share	5.34
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.06 per share	N/A
VCEL Vericel	$237.22M	7.73	$0.32 per share	114.85	$6.08 per share	5.98
XENE Xenon Pharmaceuticals	$9.43M	316.54	N/A	N/A	$8.22 per share	4.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.33	19.54	34.20	6.68	21.80%	14.69%	9.41%	11/5/2025 (Estimated)
AVXL Anavex Life Sciences	-$43M	-$0.57	N/A	N/A	N/A	N/A	-45.67%	-40.21%	N/A
VCEL Vericel	$10.36M	$0.12	303.03	82.64	N/A	2.85%	2.47%	1.69%	11/6/2025 (Estimated)
XENE Xenon Pharmaceuticals	-$234.33M	-$3.55	N/A	N/A	N/A	N/A	-38.50%	-36.47%	11/11/2025 (Estimated)

Latest AVXL, XENE, ACAD, and VCEL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q3 2025	AVXL Anavex Life Sciences	-$0.13	-$0.16	-$0.03	-$0.16	N/A	N/A
8/11/2025	Q2 2025	XENE Xenon Pharmaceuticals	-$1.03	-$1.07	-$0.04	-$1.07	N/A	N/A
8/6/2025	Q2 2025	ACAD ACADIA Pharmaceuticals	$0.14	$0.16	+$0.02	$0.16	$263.07 million	$264.57 million
7/31/2025	Q2 2025	VCEL Vericel	-$0.04	-$0.01	+$0.03	-$0.01	$64.61 million	$63.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.91	2.83
AVXL Anavex Life Sciences	N/A	8.93	8.93
VCEL Vericel	N/A	4.97	4.56
XENE Xenon Pharmaceuticals	N/A	15.14	15.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
AVXL Anavex Life Sciences	31.55%
VCEL Vericel	N/A
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.50%
AVXL Anavex Life Sciences	11.40%
VCEL Vericel	5.20%
XENE Xenon Pharmaceuticals	4.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	168.71 million	124.00 million	Optionable
AVXL Anavex Life Sciences	40	85.89 million	76.10 million	Optionable
VCEL Vericel	300	50.46 million	47.84 million	Optionable
XENE Xenon Pharmaceuticals	210	77.11 million	73.97 million	Optionable

AVXL, XENE, ACAD, and VCEL Headlines

Recent News About These Companies

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 29 at 4:10 PM | financialpost.comF

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 29 at 4:01 PM | globenewswire.com

Xenon Pharmaceuticals Inc. $XENE Shares Acquired by Affinity Asset Advisors LLC

August 28 at 9:02 AM | marketbeat.com

Russell Investments Group Ltd. Has $2.53 Million Stock Position in Xenon Pharmaceuticals Inc. $XENE

August 27 at 3:39 AM | marketbeat.com

Xenon Pharmaceuticals Inc. $XENE Shares Sold by T. Rowe Price Investment Management Inc.

August 26 at 4:49 AM | marketbeat.com

EntryPoint Capital LLC Makes New $298,000 Investment in Xenon Pharmaceuticals Inc. $XENE

August 25, 2025 | marketbeat.com

Did Higher-Than-Expected Losses Just Shift Xenon Pharmaceuticals' (XENE) Investment Narrative?

August 24, 2025 | finance.yahoo.com

Wellington Management Group LLP Has $127.13 Million Position in Xenon Pharmaceuticals Inc. $XENE

August 24, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. $XENE Shares Sold by Atika Capital Management LLC

August 23, 2025 | marketbeat.com

Candriam S.C.A. Lowers Holdings in Xenon Pharmaceuticals Inc. $XENE

August 23, 2025 | marketbeat.com

Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)

August 23, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. $XENE Shares Sold by Algert Global LLC

August 22, 2025 | marketbeat.com

An Intrinsic Calculation For Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Suggests It's 44% Undervalued

August 21, 2025 | finance.yahoo.com

Xenon Pharmaceuticals Inc. $XENE Shares Acquired by Aberdeen Group plc

August 21, 2025 | marketbeat.com

Lord Abbett & CO. LLC Sells 106,990 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

August 19, 2025 | marketbeat.com

What is Chardan Capital's Forecast for XENE FY2025 Earnings?

August 19, 2025 | marketbeat.com

XENE FY2025 EPS Estimate Decreased by Cantor Fitzgerald

August 16, 2025 | marketbeat.com

HC Wainwright Analysts Decrease Earnings Estimates for XENE

August 16, 2025 | marketbeat.com

Q3 EPS Estimate for Xenon Pharmaceuticals Lifted by Analyst

August 16, 2025 | marketbeat.com

William Blair Has Negative Estimate for XENE Q3 Earnings

August 16, 2025 | marketbeat.com

What is William Blair's Estimate for XENE FY2027 Earnings?

August 15, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL, XENE, ACAD, and VCEL Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$25.99 -0.24 (-0.91%)

Closing price 04:00 PM Eastern

Extended Trading

$25.83 -0.16 (-0.62%)

As of 07:09 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Anavex Life Sciences NASDAQ:AVXL

$9.64 +0.42 (+4.56%)

Closing price 04:00 PM Eastern

Extended Trading

$9.68 +0.04 (+0.41%)

As of 07:31 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Vericel NASDAQ:VCEL

$36.36 +0.47 (+1.31%)

Closing price 04:00 PM Eastern

Extended Trading

$36.19 -0.17 (-0.48%)

As of 06:53 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Xenon Pharmaceuticals NASDAQ:XENE

$38.71 +0.11 (+0.28%)

Closing price 04:00 PM Eastern

Extended Trading

$38.70 -0.02 (-0.04%)

As of 04:20 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time